Chromium Glycinate

Chromium glycinate is a chelated form of the essential trace mineral chromium bound to the amino acid glycine, designed to enhance bioavailability over inorganic chromium salts. It is theorized to support insulin signaling by potentiating insulin receptor tyrosine kinase activity via the chromodulin oligopeptide pathway, though human clinical evidence remains absent.

Origin & History

Chromium glycinate is a chelated mineral compound formed by binding chromium with the amino acid glycine, resulting in a complex with molecular formula C₆H₁₂CrN₃O₆ and molecular weight of 274.17 g/mol. This organic form of chromium is synthesized through chelation processes designed to enhance absorption and bioavailability compared to inorganic chromium salts.

Historical & Cultural Context

The research dossier contains no information about historical or traditional use of chromium glycinate in any medical system. The compound appears to be a modern chelated supplement form without documented traditional medicine applications.

Health Benefits

• No clinical benefits can be verified - the research dossier contains no human trials or clinical outcome data
• Chemical stability under ordinary storage conditions suggests safe supplementation potential (evidence quality: chemical data only)
• Water solubility (2% solution appears clear) indicates potential for good absorption (evidence quality: in-vitro property)
• Chelation with glycine theoretically enhances bioavailability versus inorganic forms (evidence quality: theoretical)
• Minimum 10% w/w chromium content provides standardized dosing (evidence quality: manufacturing specification)

How It Works

Chromium is hypothesized to activate chromodulin (also called low-molecular-weight chromium-binding substance, LMWCr), an oligopeptide that potentiates insulin receptor tyrosine kinase activity, amplifying downstream glucose transporter GLUT4 translocation to cell membranes. The glycinate chelation is intended to protect chromium ions from forming insoluble hydroxides in the gastrointestinal tract, theoretically increasing intestinal absorption compared to chromium chloride. No in vitro or in vivo mechanistic data specific to the chromium glycinate chelate form have been published to confirm these pathways operate differently than other chromium species.

Scientific Research

The research dossier contains no clinical trials, randomized controlled trials, meta-analyses, or PubMed PMIDs evaluating chromium glycinate's clinical efficacy in humans. The available data consists solely of chemical structure and synthesis information for tris(glycinato)chromium(III) complexes, without any therapeutic effectiveness data or clinical outcome measures.

Clinical Summary

As of current available data, no published human clinical trials specifically investigate chromium glycinate as an intervention for any health outcome, including glycemic control, body composition, or lipid metabolism. Related chromium chelates such as chromium picolinate have been studied in randomized controlled trials with sample sizes ranging from 20 to 200 participants, showing modest reductions in fasting glucose (approximately 1–2 mmol/L in some insulin-resistant populations), but these findings cannot be directly extrapolated to chromium glycinate. The existing dossier for chromium glycinate contains only chemical characterization data, including solubility and stability profiles, which represent the lowest tier of evidence for establishing clinical efficacy. Independent replication in well-controlled human trials is necessary before any health claims can be substantiated for this specific chelate form.

Nutritional Profile

Chromium Glycinate is a chelated mineral complex in which trivalent chromium (Cr³⁺) is bound to the amino acid glycine, typically in a 1:2 or 1:3 metal-to-ligand ratio. Key nutritional details: • **Chromium content**: Approximately 12–14% elemental chromium by weight (varies by manufacturer; e.g., a compound with molecular weight ~238–311 g/mol depending on hydration and stoichiometry yields roughly 52 mg Cr per ~400 mg of chelate). • **Glycine content**: Approximately 55–65% by weight, providing a modest source of the non-essential amino acid glycine (~150–260 mg per typical serving of chelate). • **No macronutrients**: Negligible calories, no fat, no fiber, no carbohydrates in supplemental doses. • **No vitamins or additional micronutrients**: The compound delivers only chromium and glycine. • **Typical supplemental dose**: Products generally standardize to 200–1000 µg elemental chromium per serving (aligned with common chromium supplement dosing; adequate intake for adults is 25–35 µg/day per IOM guidelines). • **Bioactive compound**: Trivalent chromium (Cr³⁺) is the biologically relevant oxidation state, proposed to participate in chromodulin (low-molecular-weight chromium-binding substance) activity related to insulin signaling. • **Bioavailability notes**: Chelation with glycine is intended to improve absorption over inorganic chromium salts (e.g., chromium chloride, ~0.4–2% absorption). The glycinate chelate form theoretically enhances intestinal uptake via amino acid transport pathways, with estimated absorption potentially in the range of 2–8%, though robust human pharmacokinetic data specific to chromium glycinate are limited. Water solubility (clear at 2% solution concentration) supports dissolution in the GI tract, a prerequisite for absorption. Compared to chromium picolinate (~2–5% absorption) or chromium nicotinate, glycinate chelation may offer comparable or modestly improved bioavailability, but direct head-to-head human bioavailability studies are scarce. • **Safety note**: Delivers chromium in the trivalent (Cr³⁺) form, which has a wide margin of safety; no tolerable upper intake level has been established by the IOM due to low toxicity risk at supplemental doses.

Preparation & Dosage

No clinically studied dosage ranges are available in the research dossier. The product contains a minimum of 10% w/w total chromium and 6% w/w total nitrogen. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Insufficient research data to recommend synergistic ingredients

Safety & Interactions

Chromium glycinate has no published human safety or toxicology trials, though chromium as a mineral is generally recognized as having low acute toxicity at supplemental doses, with tolerable upper intake levels not formally established by the Institute of Medicine due to insufficient adverse event data. High-dose chromium supplementation across all forms has been associated with rare reports of renal and hepatic dysfunction, cognitive impairment, and potential DNA damage via oxidative mechanisms at supraphysiological concentrations. Chromium may interact with insulin and oral hypoglycemic agents such as metformin by additively lowering blood glucose, increasing hypoglycemia risk, and may reduce the absorption of thyroid medications including levothyroxine if taken concurrently. Pregnant and breastfeeding individuals should avoid supplemental chromium glycinate beyond established adequate intake levels (30 mcg/day for pregnant adults) due to the complete absence of safety data for this specific chelate form.